Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, ...

Wegovy is the first GLP-1 treatment approved for MASH. Read more at straitstimes.com. Read more at straitstimes.com.

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

Novo Nordisk's (NVO) corrections amid AI market rotation might be an opportunity, due to GLP-1 market leadership & balanced ...

The cost of Mounjaro, a popular weight-loss injection, is set to rise sharply in the UK – from £122 to £330 – a 170 per cent increase starting this September. The price hike, confirmed by US ...

It’s no secret that obesity is becoming an epidemic in the United  States. It’s estimated that by 2030, 50 percent of Americans will be obese. But the reality  is, it’s not just Americans.   According ...

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

( NewsNation) — The National Institute for Health and Care Excellence is calling on healthcare services to offer structured ...